ATE383370T1 - Verbindungen die p-selectin binden - Google Patents

Verbindungen die p-selectin binden

Info

Publication number
ATE383370T1
ATE383370T1 AT03792179T AT03792179T ATE383370T1 AT E383370 T1 ATE383370 T1 AT E383370T1 AT 03792179 T AT03792179 T AT 03792179T AT 03792179 T AT03792179 T AT 03792179T AT E383370 T1 ATE383370 T1 AT E383370T1
Authority
AT
Austria
Prior art keywords
compounds
selectin
binding
bind
derivatives
Prior art date
Application number
AT03792179T
Other languages
English (en)
Inventor
Chantal Appeldoorn
Erik Biessen
Thomas Molenaar
Johan Lacdr Kuiper
Berkel Theodorus Van
Original Assignee
Astellas Pharma Europ B V
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astellas Pharma Europ B V filed Critical Astellas Pharma Europ B V
Application granted granted Critical
Publication of ATE383370T1 publication Critical patent/ATE383370T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1016—Tetrapeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Transplantation (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Peptides Or Proteins (AREA)
AT03792179T 2002-08-09 2003-07-04 Verbindungen die p-selectin binden ATE383370T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP02078308 2002-08-09

Publications (1)

Publication Number Publication Date
ATE383370T1 true ATE383370T1 (de) 2008-01-15

Family

ID=31896910

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03792179T ATE383370T1 (de) 2002-08-09 2003-07-04 Verbindungen die p-selectin binden

Country Status (11)

Country Link
US (3) US20060217294A1 (de)
EP (1) EP1527086B1 (de)
JP (2) JP4563806B2 (de)
AT (1) ATE383370T1 (de)
AU (1) AU2003250899A1 (de)
BR (1) BR0313019A (de)
CA (1) CA2493471C (de)
DE (1) DE60318585T2 (de)
ES (1) ES2299749T3 (de)
MX (1) MXPA05001599A (de)
WO (1) WO2004018502A1 (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003250899A1 (en) * 2002-08-09 2004-03-11 Astellas Pharma Europe B.V. Compounds binding to p-selectin
EP1549658B1 (de) 2002-10-11 2009-09-30 Astellas Pharma Europe B.V. Verbindungen auf glukosebasis mit affinitüt für p-selektin
EP1577289A1 (de) * 2004-03-18 2005-09-21 Revotar Biopharmaceuticals AG Nicht-glykosylierte/-glykosidische/-peptidische keine Moleküle als Selektininhibitoren für die Behandlung entzündlicher Erkrankungen.
EP1764093A1 (de) 2005-09-20 2007-03-21 Revotar Biopharmaceuticals AG Neue aromatische Verbindungen und deren medizinische Verwendung
EP1764096A1 (de) 2005-09-20 2007-03-21 Revotar Biopharmaceuticals AG Neue Phloroglucinolderivate mit Selectin-Ligand-Aktivität
EP1764095A1 (de) 2005-09-20 2007-03-21 Revotar Biopharmaceuticals AG Neue Nitrocatecholderivate mit Selectin-Ligand-Activität
EP2289564A3 (de) * 2006-09-08 2012-11-14 Piramal Imaging SA Anilinderivative als Edukte zur F18-Markierung
MX365465B (es) 2013-03-21 2019-06-04 Sanofi Aventis Deutschland Sintesis de productos peptidicos que contienen imida ciclica.
SG11201506804VA (en) 2013-03-21 2015-09-29 Sanofi Aventis Deutschland Synthesis of hydantoin containing peptide products

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994005314A1 (en) * 1992-09-08 1994-03-17 Centocor, Inc. Peptide inhibitors of leukocyte adhesion
AU2958195A (en) * 1994-06-29 1996-01-25 Texas Biotechnology Corporation Process to inhibit binding of the integrin alpha 4 beta 1 to vcam-1 or fibronectin
AU1471300A (en) * 1998-11-06 2000-05-29 Trustees Of The University Of Pennsylvania, The Compositions and methods for treatment of cancer
EP1288222A1 (de) * 2001-09-03 2003-03-05 Yamanouchi Europe B.V. Selektiv P-Selectin bindende peptidische Verbindungen
AU2003250899A1 (en) * 2002-08-09 2004-03-11 Astellas Pharma Europe B.V. Compounds binding to p-selectin

Also Published As

Publication number Publication date
ES2299749T3 (es) 2008-06-01
DE60318585D1 (de) 2008-02-21
EP1527086B1 (de) 2008-01-09
CA2493471A1 (en) 2004-03-04
WO2004018502A1 (en) 2004-03-04
WO2004018502A8 (en) 2005-05-12
AU2003250899A1 (en) 2004-03-11
JP2010209088A (ja) 2010-09-24
US20100323969A1 (en) 2010-12-23
MXPA05001599A (es) 2005-08-19
CA2493471C (en) 2013-02-12
US20090062186A1 (en) 2009-03-05
DE60318585T2 (de) 2009-01-08
EP1527086A1 (de) 2005-05-04
BR0313019A (pt) 2005-07-12
JP2006513141A (ja) 2006-04-20
JP4563806B2 (ja) 2010-10-13
US20060217294A1 (en) 2006-09-28

Similar Documents

Publication Publication Date Title
IS7965A (is) Þíenópýrimidíndíón og notkun þeirra í breytingu ásjálfsnæmissjúkdómi
DE602004025101D1 (de) Humane anti-humane cd3-bindungsmoleküle
SG144925A1 (en) Methods for treating cardiovascular disease using a soluble ctla4 molecule
EA200602196A1 (ru) Производные пиразола, композиции, содержащие эти соединения, и способы применения
BRPI0513681A (pt) composição que compreendem anticorpo her2, método, formulações farmacêuticas, polipeptìdeo, anticorpo e método de tratamento de cáncer
CA2413190A1 (en) Methods for treating rheumatic diseases using a soluble ctla4 molecule
CY1109168T1 (el) Συνθεση νατριουχου φονταπαρινοξης υψηλης καθαροτητας
ATE409181T1 (de) Proteomimetische verbindungen und verfahren
BRPI0413728A (pt) muteìnas de lipocalina da lágrima
DE60028970D1 (de) An her2 bindende peptidverbindungen
WO2004010957A3 (en) Drug conjugates and their use for treating cancer, an autoimmune disease or an infectious disease
DE602007009995D1 (de) Muteine von tearlipocalin und verfahren zu deren gewinnung
NZ543467A (en) The severe acute respiratory syndrome coronavirus
DK1599478T3 (da) Dihydropteridinoner, fremgangsmåde til fremstilling af disse og anvendelse af disse som lægemiddel
EA200800564A1 (ru) Производные ксантина как селективные агонисты нм74а
ZA200508389B (en) Humanized antibodies to interferon alpha receptor-1(IFNAR-1)
ATE350377T1 (de) Substituierte 3-pyrrolidin-indol-derivate
EA200702375A1 (ru) Производные мочевины, способы их получения и применения
BR0311189A (pt) Composições farmacêuticas contendo polimorfo a de flibanserin
ATE383370T1 (de) Verbindungen die p-selectin binden
DE602005019722D1 (de) Substituierte pyrrolidin-2-one
ATE482933T1 (de) Sulfopyrrolderivate
BR0311491A (pt) Composto, composição farmacêutica, uso de um composto, e, método terapêutico para tratar câncer em um mamìfero
BRPI0621347B8 (pt) composição farmacêutica para aumentar a produção de eritrócitos e para o tratamento de anemia
ATE371724T1 (de) Behandlung neurodegenerativer krankheiten

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties